HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

MRNA

Moderna, Inc. (Nasdaq 100, S&P 500)

Healthcare — Biotechnology

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Hold 2.8 / 5 18 analysts
$188.94
$-3.63 (-1.89%)
Target: $120.67 (-36.1%)

Price History

52-Week Range
Sign in to add MRNA to a watchlist or set price alerts.

Fundamentals

Market Cap$75.43B
P/E Ratio (TTM)-
Forward P/E-42.45
EPS (TTM)$-7.97
Dividend Yield-
Profit Margin-141.43%
Revenue Growth2.10%
ROE-39.00%
Debt/Equity19.04
Recommendation Hold 2.8
Analyst Target$120.67
Analysts18
Next Earnings Jul 31, 2026 BMO
Indexes Nasdaq 100 S&P 500

Technical Indicators

RSI (14)74.4
Beta1.11
SMA 20$165.64
SMA 40$137.26
52-Week High$208.90
52-Week Low$22.28
50-Day Avg$118.36
200-Day Avg$66.79
Avg Volume$17.21M
Volume$15.40M

Performance Analysis

NEUTRAL

MRNA presents a mixed picture with both positive and negative indicators.

+ Showing strength at 89% of its 52-week range.
- RSI at 74.4 indicates overbought conditions — a pullback may be due.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
~ Modest revenue growth of 2.1% year-over-year.
- Operating at a loss with -141.4% margin.
~ Wall Street consensus is "Hold" from 18 analysts.
- Average analyst target of $120.67 implies 36.1% downside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Oct 01, 2026 21:01 UTC

Back to Screener Export Report